Marlen Lauffer is a senior researcher at the Dutch Center for RNA Therapeutics where she is responsible for identifying suitable candidates for individualized ASO treatments and overseeing the practical work at the lab in Leiden. She was trained as a medical doctor and human geneticist in Germany, Switzerland, Australia, and the UK; and has been working on rare neurogenetic disorders for the past decade. Marlen is currently co-leading the Patient Identification workgroup of the N1C.